-
Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications Hematol. Oncol. (IF 3.3) Pub Date : 2024-09-21 N. Polverelli, M. Anghilieri, C. Elena, T. Intermesoli, E. Pungolino, M. D’Adda, A. Iurlo, M. Maffioli, F. Lunghi, V. Bertolli, N. Orofino, C. Sissa, C. Fiamenghi, A. Gardellini, M. Ubezio, M. C. Carraro, P. Corradini, F. Giglio, M. C. Pasquini, R. Palazzolo, R. Calori, M. Ercolanoni, C. Gambacorti‐Passerini
Lombardy represents the largest region of Italy by population, with almost 10 million residents, a dimension similar to a medium size country like Sweden or Belgium. The CML subcommittee of the Lombardy Hematology Network (REL‐CML) conducted a study at the beginning of 2023. Prevalence was calculated by direct input from the 21 centers participating in REL‐CML. Tyrosine Kinase Inhibitors (TKI) prescription
-
Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects Hematol. Oncol. (IF 3.3) Pub Date : 2024-09-14 Daniele Cattaneo, Cristina Bucelli, Valentina Bellani, Barbara Mora, Alessandra Iurlo
The therapeutic armamentarium of chronic myeloid leukemia (CML) has dramatically improved after small molecule tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 became available, with a life expectancy now close to that of the general population. Although highly effective, these drugs also have a toxicity profile that is often mild to moderate, but sometimes severe. Indeed, long‐term treatment
-
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax Hematol. Oncol. (IF 3.3) Pub Date : 2024-09-14 Stefano Cordella, Davide Giusti, Eleonora De Bellis, Michelina Dargenio, Federica Creti’, Davide Lazzarotto, Chiara Cattaneo, Nicola Stefano Fracchiolla, Matteo Piccini, Fabio Forghieri, Livio Pagano, Anna Candoni
-
Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials Hematol. Oncol. (IF 3.3) Pub Date : 2024-09-13 Mohammed Zuber, Samruddhi Nandkumar Borate, Pooja Gokhale, Akhila Yerubandi, N. M. Mahmudul Alam Bhuiya, Smita Rawal, Henry N. Young, Lorenzo Villa Zapata
Bruton's tyrosine kinase (BTK) inhibitors are important therapeutic advances with promising efficacy outcomes in the treatment of patients with chronic lymphocytic leukemia and other B‐cell lymphoma subtypes. However, the utility of BTK inhibitors can be limited by adverse events such as infections. In this systematic review and meta‐analysis, we aim to determine the risk of various infections associated
-
Research on the mechanism of HOPX‐HDAC2 interaction inducing differentiation blockage in acute myeloid leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-09-07 Fang He, Yan Tu, Lihong Ni
Homeodomain‐only protein homeobox (HOPX) mainly exerts its transcriptional repression by physically sequestering the serum co‐repressor and recruiting histone deacetylase (HDAC), possessing important potential as a prognostic gene in acute myeloid leukemia (AML). HDACs play crucial roles in cell growth, gene regulation, and metabolism, and they are also important factors in promoting AML progression
-
Combined targeting of Hedgehog/GLI1 and Wnt/β‐catenin pathways in mantle cell lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2024-08-29 Yan Han, Chuntuan Li, Shengquan Liu, Jingjing Gao, Yanjun He, Huifang Xiao, Qi Chen, Yan Zheng, Hongyuan Chen, Xiongpeng Zhu
Mantle cell lymphoma (MCL) is a rare and aggressive form of non‐Hodgkin lymphoma. Challenges in its treatment include relapse, drug resistance, and a short survival period. The Hedgehog/GLI1 (Hh/GLI1) and Wnt/β‐catenin pathways are crucial in cancer cell proliferation, survival, and drug resistance, making them significant targets for anticancer research. This study aimed to assess the effectiveness
-
Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single‐center retrospective analysis Hematol. Oncol. (IF 3.3) Pub Date : 2024-08-14 Marie Anne‐Catherine Neumann, Jan‐Hendrik Naendrup, Jorge Garcia Borrega, Ismini Halmer, Lisa Altenrath, Noelle Sieg, Michael Hallek, Dennis A. Eichenauer, Jan‐Michel Heger
The overall prognosis of older patients with acute myeloid leukemia (AML) is dismal. Only a small subgroup experiences long‐term survival. The discrimination between patients who are candidates for potentially curative approaches and those who are not is crucial since ‐ in addition to differences in terms of AML‐directed treatment ‐ different policies concerning intensive care unit (ICU) admission
-
Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD Hematol. Oncol. (IF 3.3) Pub Date : 2024-08-12 Carmen Martínez, Esther Carcelero, Antonio Gutiérrez, Esther Sancho, Josep Maria Martí‐Tutusaus, Laura Magnano, Pablo Mozas, Francesc Fernández‐Avilés, María Gabriela Antelo, Xavier Setoain, Sonia Rodríguez, Jordi Esteve
Patients with advanced‐stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG‐PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression‐free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A‐AVD escalation treatment outcomes for 15 iPET‐positive patients post‐ABVD. Overall response
-
Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting Hematol. Oncol. (IF 3.3) Pub Date : 2024-08-09 Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura‐Yogo, Yuki Oda, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida
-
From trials to statistical insights: Bortezomib's story in childhood T‐cell lymphoid malignancies Hematol. Oncol. (IF 3.3) Pub Date : 2024-08-07 Shyam Srinivasan
-
Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group Hematol. Oncol. (IF 3.3) Pub Date : 2024-08-06 Evgenia Verrou, Sotirios G. Papageorgiou, Maria Bouzani, Aggeliki Sevastoudi, Theodora Triantafyllou, Aikaterini Daiou, Dimitra Dalampira, Maria Arapaki, Chara Giatra, Anastasia Banti, Gerasimos Kyriakidis, Dionisios Stoumpos, Nikolaos Karampatzakis, Theodosia Papadopoulou, Maria Kotsopoulou, Anastasia Pouli, Evdokia Mandala, Vassiliki Pappa, Emmanouil Spanoudakis, Eirini Katodritou, Theodoros P. Vassilakopoulos
Involvement of female genital track (FGT) by diffuse large B cell lymphoma (DLBCL) represents an extremely rare diagnosis. Especially data regarding early‐stage disease (i.e., IE, IIE) is very limited. Importantly, previous studies showed controversial results about the risk of central nervous system (CNS) relapse in this entity. Herein, we describe one of the largest reported real‐world series of
-
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study Hematol. Oncol. (IF 3.3) Pub Date : 2024-08-06 Beatrice Casadei, Gabriele Conti, Monica Barone, Silvia Turroni, Serafina Guadagnuolo, Alessandro Broccoli, Patrizia Brigidi, Lisa Argnani, Pier Luigi Zinzani
Biomarkers for immune checkpoint inhibitors (ICIs) response and resistance include PD‐L1 expression and other environmental factors, among which the gut microbiome (GM) is gaining increasing interest especially in lymphomas. To explore the potential role of GM in this clinical issue, feces of 30 relapsed/refractory lymphoma (Hodgkin and primary mediastinal B‐cell lymphoma) patients undergoing ICIs
-
Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies Hematol. Oncol. (IF 3.3) Pub Date : 2024-08-03 Taku Kikuchi, Yuki Oda, Ukyo Kondo, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura‐Yogo, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida
To retrospectively analyze whether the second revision of the international staging system (R2‐ISS) influenced prognosis at treatment initiation in patients with multiple myeloma (MM) receiving anti‐CD38 antibody‐based triplet treatments. High‐risk chromosomal abnormalities were examined from diagnosis to treatment initiation and considered positive if detected once. R2‐ISS was recalculated at the
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2024-07-29
No abstract is available for this article.
-
Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial Hematol. Oncol. (IF 3.3) Pub Date : 2024-07-23 Xiaohui Suo, Zheng Fang, Dongmei Wang, Liyun Zhao, Jie Liu, Hong Li, Xiaojun Ma, Congcong Zhang, Xuemei Zhao, Rui Shi, Yan Wu, Zongjiu Jiao, Jiaojie Song, Ling Zhang, Ling Li, Suping Zhang, Xinxiao Lu, Linyu Yuan, Sifeng Gao, Jilei Zhang, Kaiqi Liu, Xingli Zhao, Guanchen Bai, Yingchang Mi
-
Prescription patterns of venetoclax in acute myeloid leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-07-11 Andrealuna Ucciero, Giuseppe Traversa, Alessia Pisterna, Valeria Cardinali, Sofia Sciabolacci, Antonella Poloni, Debora Capelli, Gianluca Gaidano, Andrea Patriarca, Monia Lunghi
-
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital Hematol. Oncol. (IF 3.3) Pub Date : 2024-07-11 Caroline Le Lan, Aurélien Belot, Camille Golfier, Bérénice Audin, Pierre Sesques, Adeline Bernier, Violaine Safar, Emmanuelle Ferrant, Anne Lazareth, Hélène Lequeu, Lionel Karlin, Dana Ghergus, Alizée Maarek, Guillaume Aussedat, Maryam Idlhaj, Gilles Salles, Fanny Cherblanc, Emmanuel Bachy, Hervé Ghesquieres
-
TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation Hematol. Oncol. (IF 3.3) Pub Date : 2024-07-09 Chunxiang Xiang, Limin Gao, Qing Tao, Zihang Chen, Sha Zhao, Weiping Liu
The biological role of Ten‐11 translocation 2 (TET2) and the conversion of 5‐methylcytosine (5mC) to 5‐hydroxymethylcytosine (5hmC) in the development of extra‐nodal natural killer/T‐cell lymphoma (ENKTL) remains unclear. The level of 5mC and 5hmC was detected in 112 cases of ENKTL tissue specimens by immunohistochemical (IHC) staining. Subsequently, TET2 knockdown and the overexpression cell models
-
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy. Hematol. Oncol. (IF 3.3) Pub Date : 2024-07-01 Danai Dima,Utkarsh Goel,Aishwarya Sannareddy,Nnaemeka Ibeh,Fauzia Ullah,Aimaz Afrough,Sandra Mazzoni,Ali Mehdi,Joslyn Rudoni,Shahzad Raza,Nicole De Simone,Louis Williams,Adeel Khan,Aliya Rashid,Mikhaila Rice,Kristin Ricci,Christy Samaras,Jason Valent,Larry D Anderson,Faiz Anwer,Gurbakhash Kaur,Jack Khouri
Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell-directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi-institutional study was to evaluate the clinical outcomes
-
Clonal dynamics of Richter transformation in chronic lymphocytic leukemia. Hematol. Oncol. (IF 3.3) Pub Date : 2024-07-01 Hanyin Wang,Shulan Tian,Charla R Secreto,Sutapa Sinha,Min Shi,Timothy Call,Yucai Wang,Sameer A Parikh,Saad S Kenderian,Rong He,Jose F Leis,Daniel L VanDyke,Eric W Klee,Susan L Slager,Esteban Braggio,Huihuang Yan,Wei Ding
-
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematol. Oncol. (IF 3.3) Pub Date : 2024-07-01 Claudia Bellofiore,Pietro Benvenuti,Roberto Mina,Marco Basset,Andrea Foli,Martina Nanci,Mario Nuvolone,Gianluigi Guida,Andrea Attanasio,Roberta Mussinelli,Silvia Mangiacavalli,Claudio Salvatore Cartia,Valeria Masoni,Michele Palumbo,Lorenzo Cani,Stefania Oliva,Ugo Consoli,Concetta Conticello,Francesco Di Raimondo,Luca Arcaini,Sara Bringhen,Giampaolo Merlini,Giovanni Palladini,Paolo Milani
Daratumumab-based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real-world data on daratumumab efficacy in upfront therapy in unselected patients are scanty. In the framework of a prospective observational study, we investigated the efficacy and safety of daratumumab in 88 newly diagnosed patients, including
-
Correction to Staging FDG‐avidity in extranodal marginal zone lymphoma (EMZL) by disease location Hematol. Oncol. (IF 3.3) Pub Date : 2024-06-21
-
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials Hematol. Oncol. (IF 3.3) Pub Date : 2024-05-31 Enrica Antonia Martino, Salvatore Palmieri, Monica Galli, Daniele Derudas, Roberto Mina, Roberta Della Pepa, Renato Zambello, Ernesto Vigna, Antonella Bruzzese, Silvia Mangiacavalli, Elena Zamagni, Catello Califano, Maurizio Musso, Concetta Conticello, Claudio Cerchione, Giuseppe Mele, Nicola Di Renzo, Massimo Offidani, Giuseppe Tarantini, Gloria Margiotta Casaluci, Angela Rago, Roberto Ria, Giuseppina
The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18‐month follow‐up update of a previously published Italian
-
Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes Hematol. Oncol. (IF 3.3) Pub Date : 2024-05-31 Xiaohui Wang, Hengqi Liu, Yue Fei, Zheng Song, Xiangrui Meng, Jingwei Yu, Xia Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianhuo Wang, Huilai Zhang
Diffuse large B‐cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease that requires personalized clinical treatment. Assigning patients to different risk categories and cytogenetic abnormality and genetic mutation groups has been widely applied for prognostic stratification of DLBCL. Increasing evidence has demonstrated that dysregulated metabolic processes contribute to the
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2024-05-31
No abstract is available for this article.
-
FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-05-22 María Turos‐Cabal, Ana M. Sánchez‐Sánchez, Noelia Puente‐Moncada, Federico Herrera, Isaac Antolin, Carmen Rodríguez, Vanesa Martín
The FLT3‐ITD mutation represents the most frequent genetic alteration in newly diagnosed acute myeloid leukemia (AML) patient and is associated with poor prognosis. Mutation result in the retention of a constitutively active form of this receptor in the endoplasmic reticulum (ER) and the subsequent modification of its downstream effectors. Here, we assessed the impact of such retention on ER homeostasis
-
Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study Hematol. Oncol. (IF 3.3) Pub Date : 2024-05-14 Anna Panovská, Pavel Žák, Tereza Jurková, Tomáš Arpáš, Yvona Brychtová, Alžběta Vašíková, Viera Hrabčáková, Adéla Prchlíková, Martina Filipová, Michael Doubek
Hairy cell leukemia (HCL) and HCL‐like disorders have to be distinguished because of their different biology and treatment response. Thus, we conducted a retrospective study on patients with HCL and hairy cell leukemia variant (HCLv) to assess diagnostic algorithms and treatment outcomes in a real‐world setting. We analyzed 225 HCL and 26 HCLv patients with median follow‐up of 67.9 months (HCL) and
-
Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients Hematol. Oncol. (IF 3.3) Pub Date : 2024-05-10 Kaitlin Annunzio, Subodh Bhatta, Walter Hanel, Qiuhong Zhao, Mackenzie Owen, Havi Rosen, Timothy J. Voorhees, David A. Bond, Yazeed Sawalha, Audrey M. Sigmund, Lapo Alinari, Robert A. Baiocchi, Kami J. Maddocks, Daniel Jones, Beth Christian, Narendranath Epperla
Follicular lymphoma (FL) is the most common indolent B‐cell non‐Hodgkin lymphoma. Circulating lymphoma (CL) cells can be seen at diagnosis in some FL patients, however, previous studies evaluating this have shown mixed results. Therefore, we sought to evaluate the impact of CL at diagnosis on outcomes in patients with newly diagnosed FL using data from a single center. Patients were divided into CL+
-
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-05-07 Sudhir Manda, Bertrand M. Anz, Christopher Benton, E. Randolph Broun, Habte A. Yimer, John S. Renshaw, George Geils, Jesus Berdeja, Jose Cruz, Jason M. Melear, Suzanne Fanning, Luke Fletcher, Yukun Li, Yinghui Duan, Michael E. Werner, Jalaja Potluri, Madhavi V. Pai, William B. Donnellan
Venetoclax, a highly selective BCL‐2 inhibitor, combined with hypomethylating agents (HMAs) azacitidine or decitabine, is approved for the treatment of newly diagnosed acute myeloid leukemia (ND AML) in patients who are ineligible to receive intensive chemotherapy. Previous clinical studies initiated venetoclax plus HMA in an inpatient setting owing to concerns of tumor lysis syndrome (TLS). This study
-
-
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-29 Mariarita Sciumè, Fabio Serpenti, Roberta Zanotti, Patrizia Bonadonna, Ilaria Tanasi, Lara Crosera, Chiara Elena, Francesco Mannelli, Francesca Crupi, Cristina Papayannidis, Chiara Sartor, Simona Soverini, Michela Rondoni, Cristina Eller‐Vainicher, Valerio Pravettoni, Federica Rivolta, Silvia Alberti Violetti, Giorgio Alberto Croci, Anna Chiara Migliorini, Niccolò Bolli, Diana Giannarelli, Federica
-
Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-27 Jiangfang Feng, Yue Fei, Meng Gao, Xiangrui Meng, Dongfeng Zeng, Dehui Zou, Haige Ye, Yun Liang, Xiuhua Sun, Rong Liang, Hui Zhou, Xianhuo Wang, Huilai Zhang
Mantle cell lymphoma (MCL) is an uncommon and incurable B‐cell lymphoma subtype that has an aggressive course. Hepatitis B virus (HBV) infection has been associated with an increased risk for B‐cell lymphomas, and is characterized by distinct clinical and genetic features. Here, we showed that 9.5% of MCL Chinese patients were hepatitis B surface antigen positive (HBsAg+). Compared to HBsAg‐negative
-
Erratum to reply to “successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients—A Czech multicenter experience”: A case series of SARS‐CoV‐2 Omicron infection and aggressive lymphoma in the Sotrovimab era Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-25
-
Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-25 Vittorio Ruggero Zilioli, Emanuele Cencini, Sonya De Lorenzo, Luca Pezzullo, Michele Merli, Flavia Rivellini, Cristina Muzi, Barbieri Emiliano, Luigi Marcheselli, Stefano Luminari
Few data are known regarding the use of interim positron emission tomography (iPET) after the first two cycles (iPET2) of chemotherapy in treatment‐naïve classical Hodgkin lymphoma (cHL) in routine clinical practice, and about the real‐life adoption of intensification strategies for iPET positive patients. We conducted a multicenter retrospective study on cHL to investigate the use of iPET in the real‐life
-
Discovery Science highlights from the 17th International Conference on Malignant Lymphoma Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-23 Gabriela Forestieri, Joyce Marques de Almeida, Sara Napoli, Deborah Piffaretti, Chiara Tarantelli, Fangwen Zhang, Afua Adjeiwaa Mensah
-
Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk‐adapted, response‐adapted, and safer than before Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-23 Jessica Saddi, Amelia Barcellini, Manuel Gotti, Alessandro Mazzacane, Alessandra Tolva, Tanja Lazic, Luca Arcaini, Marco Zecca, Ester Orlandi, Andrea Riccardo Filippi
Classical Hodgkin lymphoma is a lymphoproliferative disease with a good prognosis mainly seen in young people. Nevertheless secondary malignancy, cardiac disease and infertility may affect the long survivors with significant impact on quality of life, morbidity and overall survival. In the last decades several treatment strategies were evaluated to reduce the toxicity of first line treatment such as
-
Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-12 José Carlos Jaime‐Pérez, Marcela Hernández‐Coronado, Mariana González‐Treviño, Renata V. Barragán‐Longoria, Eugenia M. Ramos‐Dávila, David Gómez‐Almaguer
-
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203 Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-10 Takashi Watanabe, Yoshihiro Matsuno, Masashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Kunihiro Tsukasaki, Kensei Tobinai, Hirokazu Nagai
Follicular lymphoma (FL) is an indolent lymphoma that becomes aggressive due to histological transformation (HT), leading to reduced survival. Patients with FL have different clinical courses and various treatment options. Some patients exhibit shorter survival and experience disease progression within 24 months of diagnosis/treatment (POD24); the optimal treatment remains an unmet needs. Thus, identifying
-
Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-09 Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Light chain amyloidosis is a rare disease caused by clonal plasma cells in the bone marrow generating an excessive amount of immunoglobulin light chains. These chains misfold and produce insoluble fibrils that deposit in various organs, including the heart, kidneys, liver, nervous system, and digestive tract. Life expectancy and symptoms during the course of the disease vary depending on which and
-
The RAS‐signaling‐pathway‐mutation‐related prognosis in B‐cell acute lymphoblastic leukemia: A report from South China children's leukemia group Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-02 Xinyu Li, Shaofen Lin, Ning Liao, Huirong Mai, Xingjiang Long, Lili Liu, Beiyan Wu, Qiwen Chen, Qian Kong, Xianling Kong, Lixia Liu, Jiayue Qin, Jianpei Fang, Dunhua Zhou
The next‐generation sequencing technologies application discovers novel genetic alterations frequently in pediatric acute lymphoblastic leukemia (ALL). RAS signaling pathway mutations at the time of relapse ALL frequently appear as small subclones at the time of onset, which are considered as the drivers in ALL relapse. Whether subclones alterations in the RAS signaling pathway should be considered
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2024-04-02
No abstract is available for this article.
-
Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-10 Yuan Sun, Xu Wang, Wen‐Min Chen, Yue Hao, Ling‐Di Li, Jin‐Ying Li, Kai Sun, Zong‐Yan Shi, Hao Jiang, Qian Jiang, Xiao‐Jun Huang, Ya‐Zhen Qin
In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KITmut) DNA level is reportedly predictive of relapse in t (8; 21) acute myeloid leukemia (AML). However, the usefulness of KITmut transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 t (8; 21) AML patients with KITmut (D816V/H/Y
-
Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-08 Elisabetta M. Abenavoli, Flavia Linguanti, Matilde Anichini, Vittorio Miele, Francesco Mungai, Marianna Palazzo, Luca Nassi, Benedetta Puccini, Ilaria Romano, Benedetta Sordi, Roberto Sciagrà, Gabriele Simontacchi, Alessandro M. Vannucchi, Valentina Berti
To recognize patients at high risk of refractory disease, the identification of novel prognostic parameters improving stratification of newly diagnosed Hodgkin Lymphoma (HL) is still needed. This study investigates the potential value of metabolic and texture features, extracted from baseline 18F‐FDG Positron Emission Tomography/Computed Tomography (PET) and Contrast‐Enhanced Computed Tomography scan
-
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-07 Maria Anele Romeo, Chiara Focaccetti, Andrea Arena, Rossella Benedetti, Michele Di Crosta, Camilla Palumbo, Maria Saveria Gilardini Montani, Roberta Santarelli, Roberta Gonnella, Gabriella D’Orazi, Roberto Bei, Mara Cirone
-
The role of baseline 2‐[18F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-06 Domenico Albano, Anna Calabrò, Francesco Dondi, Samuele Bagnasco, Alessandra Tucci, Francesco Bertagna
Diffuse Large B‐Cell Lymphomas (DLCBL) and mucosa‐associated lymphoid tissue (MALT) are the two most common primary gastric lymphomas (PGLs), but have strongly different features. DLBCL is more aggressive, is frequently diagnosed at an advanced stage and has a poorer prognosis. The aim of this retrospective study was to explore the role of fluorine‐18‐fluorodeoxyglucose positron emission tomography/computed
-
How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia. Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-01 Nayla Mouawad,Edoardo Ruggeri,Guido Capasso,Leonardo Martinello,Andrea Visentin,Federica Frezzato,Livio Trentin
Chronic lymphocytic leukemia (CLL) is the most common leukemia in western societies, recognized by clinical and molecular heterogeneity. Despite the success of targeted therapies, acquired resistance remains a challenge for relapsed and refractory CLL, as a consequence of mutations in the target or the upregulation of other survival pathways leading to the progression of the disease. Research on proteins
-
Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy Hematol. Oncol. (IF 3.3) Pub Date : 2024-03-01 Enrico Grande, Francesco Grippo, Claudio Barbiellini Amidei, Ugo Fedeli, Alberto Tosetto
-
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-28 Rong Wang, Yi Zhang, Jie Chang, Huafeng Wang, Yinjun Lou, Min Yang, Gaixiang Xu, Hongyan Tong, Wanzhuo Xie, De Zhou, Juying Wei, Wenyuan Mai, Xiujin Ye, Haitao Meng, Jie Jin, Hong‐Hu Zhu
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy (DAV) has shown safety and efficacy in eligible patients with newly diagnosed acute myeloid leukemia (AML). However, there are no direct comparisons between DAV and 3 + 7 daunorubicin and cytarabine chemotherapy (DA) alone. We performed a propensity score‐matched analysis to compare the outcomes of DAV group with historical DA group and
-
Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-28 João L. Pereira, Francisca Ferreira, Nuno R. dos Santos
Lymphomas are a heterogeneous group of diseases that originate from T, B or natural killer cells. Lymphoma treatment is based on chemotherapy, radiotherapy, and monoclonal antibody (mAb) or other immunotherapies. The P‐selectin glycoprotein ligand 1 (PSGL‐1) is expressed at the surface of hematological malignant cells and has been shown to have a pro‐oncogenic role in multiple myeloma and lymphoma
-
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-25 Andrea Duminuco, Antonella Nardo, Giuseppe A. Palumbo
-
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-25 Thierry Facon, Philippe Moreau, Ivan Špicka, Kenshi Suzuki, Kwee Yong, Joseph Mikhael, Taro Fukao, Kamlesh Bisht, Nicole M. Armstrong, Sandrine Macé, Marie‐Laure Risse, Thomas Martin
Gain/amplification of 1q21 (≥3 copies), a chromosomal abnormality frequently observed in multiple myeloma, can negatively affect prognosis, due to its involvement in resistance to anti‐myeloma therapy and disease progression. In this updated subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285) in relapsed/refractory multiple myeloma (RRMM), we evaluated progression‐free survival (PFS)
-
Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-17 Lin-Ya Wang, Yao Li, Qian Jiang, Hao Jiang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Fei-Fei Tang
This study aimed to investigate the clinical characteristics and prognosis of Runt-related transcription factor 1 (RUNX1) mutant acute myeloid leukemia (AML) patients by comparing the features of AML patients with or without RUNX1 mutation. We retrospectively analyzed 180 AML patients including 36 AML patients with mutant RUNX1(AML-RUNX1mut) and 144 AML patients with wild-type RUNX1(AML-RUNX1wt) were
-
Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel Hematol. Oncol. (IF 3.3) Pub Date : 2024-02-16 Francesca Romana Mauro, Alessandra Tedeschi, Marzia Varettoni, Francesco Zaja, Giovanni Barosi, Pier Luigi Zinzani
Zanubrutinib has been approved for treating patients with different lymphoproliferative disorders and now represents a significant breakthrough in treating relapsed/refractory and previously untreated patients with chronic lymphocytic leukemia (CLL). Because few systematic studies or comparative randomized clinical trials have been conducted, optimal use of zanubrutinib in approved indications may
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-27
No abstract is available for this article.
-
Incidence, risk factors, and outcome of asymptomatic central nervous system involvement in adult patients with acute myeloid leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-27 Marijana Virijevic, Nada Kraguljac-Kurtovic, Mirjana Mitrovic, Ljubomir Jakovic, Zoran Bukumuric, Nikola Pantic, Nikica Sabljic, Zlatko Pravdic, Mirjana Cvetkovic, Vesna Knezevic, Tijana Dragovic-Ivancevic, Irena Djunić, Jovan Rajic, Violeta Milosevic, Milena Todorovic-Balint, Ana Vidovic, Nada Suvajdzic-Vukovic
Examination of central nervous system (CNS) involvement is not routine diagnostic practice in adult patients with acute myeloid leukemia (AML). Therefore, many asymptomatic patients with CNS involvement might go undetected. The effect of CNS involvement on the AML disease course is not well defined, with conflicting results regarding clinical outcome. This study aimed to determine the incidence of
-
ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-12 Zong-Yan Shi, Xu Wang, Wen-Min Chen, Ling-Di Li, Yue Hao, Jin-Ying Li, Kai Sun, Xiao-Su Zhao, Hao Jiang, Qian Jiang, Xiao-Jun Huang, Ya-Zhen Qin
Zinc finger protein 384 (ZNF384) rearrangement defined a novel subtype of B-cell acute lymphoblastic leukemia (B-ALL). The prognostic significance of ZNF384 fusion transcript levels represented measurable residual disease remains to be explored. ZNF384 fusions were screened out in 57 adult B-ALL patients at diagnosis by real-time quantitative polymerase chain reaction and their transcript levels were
-
Possible effects of plasminogen activator inhibitor-1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-05 Taku Fujimura, Kentaro Ohuchi, Tetsuya Ikawa, Yumi Kambayashi, Ryo Amagai, Sadanori Furudate, Yoshihide Asano
Mycosis fungoides (MF) progresses slowly before advancing to skin tumors followed by lymph node and visceral involvement. Among MF progression, stage IIB is an initial time point of tumor formation in MF. Since MF in tumor stage possess abundant blood vessels, it is important to evaluate the pro-angiogenic factors before and after MF in stage IIB. In this report, we investigated pro-angiogenic soluble
-
Diagnosis of chronic B-cell lymphoproliferative disease in peripheral blood = how machine learning may help to the interpretation of flow cytometry data Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-05 Zofia Gross, Richard Veyrat-Masson, Béatrice Grange, Sarah Huet, Aurélie Verney, Alexandra Traverse-Glehen, Philippe Ruminy, Lucile Baseggio
Flow cytometry (FCM) has become a method of choice for immunologic characterization of chronic lymphoproliferative disease (CLPD). To reduce the potential subjectivities of FCM data interpretation, we developed a machine learning random forest algorithm (RF) allowing unsupervised analysis. This assay relies on 16 parameters obtained from our FCM screening panel, routinely used in the exploration of
-
Issue Information Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-03
No abstract is available for this article.
-
Prognostic value of the second revision of the international staging system (R2-ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Hematol. Oncol. (IF 3.3) Pub Date : 2024-01-01 Taku Kikuchi,Nobuhiro Tsukada,Kodai Kunisada,Moe Yogo,Yuki Oda,Kota Sato,Tomomi Takei,Mizuki Ogura,Yu Abe,Kenshi Suzuki,Tadao Ishida